[go: up one dir, main page]

MX2023002337A - Composición y métodos para el tratamiento o profilaxis de coronavirus y cánceres. - Google Patents

Composición y métodos para el tratamiento o profilaxis de coronavirus y cánceres.

Info

Publication number
MX2023002337A
MX2023002337A MX2023002337A MX2023002337A MX2023002337A MX 2023002337 A MX2023002337 A MX 2023002337A MX 2023002337 A MX2023002337 A MX 2023002337A MX 2023002337 A MX2023002337 A MX 2023002337A MX 2023002337 A MX2023002337 A MX 2023002337A
Authority
MX
Mexico
Prior art keywords
composition
methods
prophylaxis
cancers
coronavirus
Prior art date
Application number
MX2023002337A
Other languages
English (en)
Inventor
Pablo Antonio Betancourt
Original Assignee
Betahealth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betahealth Llc filed Critical Betahealth Llc
Publication of MX2023002337A publication Critical patent/MX2023002337A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
    • C12Y301/27005—Pancreatic ribonuclease (3.1.27.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se describe una composición y métodos para tratar, reducir los síntomas o profilaxis de infecciones virales, y particularmente SARS-CoV-2. La composición mejora el suministro de oxígeno a los tejidos. También se describe en la presente una composición y métodos para tratar cánceres, particularmente adenocarcinomas, adenocarcinoma ductal infiltrante, adenocarcinoma ductal metastásico y tumores neuroendocrinos. La composición inhibe el crecimiento de células tumorales y promueve la citorreducción de tumores.
MX2023002337A 2020-08-27 2021-08-26 Composición y métodos para el tratamiento o profilaxis de coronavirus y cánceres. MX2023002337A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063071128P 2020-08-27 2020-08-27
US202063104621P 2020-10-23 2020-10-23
US202063110458P 2020-11-06 2020-11-06
US202063110485P 2020-11-06 2020-11-06
PCT/US2021/047643 WO2022046960A1 (en) 2020-08-27 2021-08-26 Composition and methods for treatment or prophylaxis of coronavirus and cancers

Publications (1)

Publication Number Publication Date
MX2023002337A true MX2023002337A (es) 2023-05-12

Family

ID=80353938

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002337A MX2023002337A (es) 2020-08-27 2021-08-26 Composición y métodos para el tratamiento o profilaxis de coronavirus y cánceres.

Country Status (4)

Country Link
US (3) US12343322B2 (es)
EP (1) EP4204550A4 (es)
MX (1) MX2023002337A (es)
WO (1) WO2022046960A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025147696A1 (en) * 2024-01-05 2025-07-10 Resolve Therapeutics, Llc Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172053B1 (en) 1999-02-24 2001-01-09 Ruben G. Fabunan Injection viral treatment
WO2006044263A2 (en) * 2004-10-12 2006-04-27 Advanced Biotherapy, Inc. Treatment of herpes
US20070128722A1 (en) * 2005-12-05 2007-06-07 Industrial Technology Research Institute Human mesenchymal stem cells and culturing methods thereof
WO2014026052A1 (en) * 2012-08-08 2014-02-13 Vanderbilt University Composition with biofilm dispersal agents
CA2942706C (en) 2014-03-28 2020-01-14 Tamir Biotechnology, Inc. Rnase for use in treating or preventing viral infections
US20200016231A1 (en) * 2016-12-22 2020-01-16 Whiteley Corporation Pty Ltd Biofilm disrupting composition
US11426405B2 (en) 2017-12-04 2022-08-30 The Brigham And Women's Hospital, Inc. Inhibition of JAK-STAT signaling inhibits formation of neutrophil extracellular traps (NETs)
WO2020106709A1 (en) * 2018-11-19 2020-05-28 Gro Biosciences Inc. Human dnase for lung disease

Also Published As

Publication number Publication date
WO2022046960A1 (en) 2022-03-03
US20220062219A1 (en) 2022-03-03
US12343322B2 (en) 2025-07-01
US12336975B2 (en) 2025-06-24
EP4204550A1 (en) 2023-07-05
US20250332136A1 (en) 2025-10-30
EP4204550A4 (en) 2024-09-25
US20230248685A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
MX2022013808A (es) Terapia de combinacion triple para mejorar la eliminacion de celulas cancerigenas en canceres con baja inmunogenicidad.
MX2022009347A (es) Terapia de combinacion para el tratamiento del crecimiento celular anormal.
BR112022020817A2 (pt) Inibidores de kif18a para tratamento de doenças neoplásicas
WO2011112953A3 (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
CO5640150A2 (es) Tratamiento con anticuerpos anti-vegf
MX2022010512A (es) Inhibidores de proteína bcl-2.
MX2023002337A (es) Composición y métodos para el tratamiento o profilaxis de coronavirus y cánceres.
MX2022012576A (es) Inhibidores de axl para terapia antiviral.
MX2023007436A (es) Arn terapeutico para tratar cancer.
MX2024011249A (es) Dosificacion no lineal de mirdametinib.
MX2025010770A (es) Formas farmaceuticas de mirdametinib
WO2023034336A3 (en) Improved treatments for advanced/metastatic cancers with checkpoint inhibitor resistance or resistance susceptibility
Ahmed et al. Oncoviruses: How do they hijack their host and current treatment regimes
MX2023011956A (es) Metodo para tratar el cancer de pulmon y el cancer de pulmon de celulas no peque?as.
MX2022014886A (es) Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab y una quimioterapia a base de oxaliplatino.
PH12022551081A1 (en) Cancer treatments targeting cancer stem cells
NZ598131A (en) Anti-angiogenesis therapy for the treatment of previously treated breast cancer
WO2024006292A3 (en) Methods of treating cancer
MX2022011646A (es) Celulas t v delta1+ para el tratamiento de neoplasias mieloides.
MX2025002312A (es) Terapias combinadas para el tratamiento de linfomas de celulas t con tolinapant, cedazuridina y decitabina
MX2022005448A (es) Método de tratamiento de queratodermia palmoplantar.
ZA202406390B (en) Compounds and their use in treating cancer
CR20230258A (es) Compuestos y composiciones de moléculas pequeñas
BR112023018921A2 (pt) Métodos para tratar câncer com anticorpos anti-ilt3
Lin et al. Phase II trial of capecitabine combined with docetaxel in previously treated patients with non-small cell lung cancer: A randomized controlled study